<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Lassa fever</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Lassa fever</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Lassa fever</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">John S Schieffelin, MD, MSPH</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Martin S Hirsch, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jennifer Mitty, MD, MPH</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> May 12, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H3717146153"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Lassa fever is a hemorrhagic illness caused by Lassa mammarenavirus virus [<a href="#rid1">1-3</a>]. Lassa fever was first recognized in Lassa, Nigeria, in 1969 and is endemic to West Africa; there are approximately 300,000 cases and 5000 deaths annually [<a href="#rid4">4-12</a>]. The animal reservoir is the rodent "multimammate rat" (<em>Mastomys natalensis</em>); transmission to humans occurs via contact with infected rodent urine and feces and via person-to-person contact [<a href="#rid4">4,13</a>]. Lassa virus is a single-stranded RNA virus belonging to the Arenaviridae family and has been classified as a category A bioterrorism agent [<a href="#rid14">14</a>].</p><p>Issues specific to Lassa fever will be reviewed here. Issues related to other causes of viral hemorrhagic fever are discussed separately:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/3022.html" rel="external">"Clinical manifestations and diagnosis of Ebola virus disease"</a> and  <a class="medical medical_review" href="/z/d/html/98084.html" rel="external">"Marburg virus"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/3025.html" rel="external">"Dengue virus infection: Clinical manifestations and diagnosis"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/102363.html" rel="external">"Crimean-Congo hemorrhagic fever"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/3032.html" rel="external">"Yellow fever: Epidemiology, clinical manifestations, and diagnosis"</a>.)</p><p></p><p class="headingAnchor" id="H622044583"><span class="h1">EPIDEMIOLOGY</span></p><p class="headingAnchor" id="H1058440233"><span class="h2">Geography</span><span class="headingEndMark"> — </span>Lassa fever is endemic in parts of West Africa including Guinea, Liberia, Sierra Leone, Nigeria, Benin, Ghana, and Mali [<a href="#rid15">15,16</a>]; other neighboring countries are also at risk as the animal vector is distributed throughout the region. Cases have been reported in Côte d’Ivoire and Burkina Faso, and there is serologic evidence of Lassa virus infection among individuals in Togo [<a href="#rid17">17-26</a>].</p><p>The prevalence of Lassa virus infections varies within endemic areas; the incidence is highest in the forested regions of West Africa where Guinea, Liberia, and Sierra Leone share a border [<a href="#rid17">17,27</a>]. Within Sierra Leone, seroprevalence rates vary from 8 percent in coastal regions to 52 percent in the Eastern Province [<a href="#rid4">4</a>]. In Guinea, the seroprevalence rate varies from 4 to 55 percent [<a href="#rid27">27-30</a>].</p><p>Cases of Lassa fever occur at all times of year; the peak incidence occurs in March, during the transition from dry to wet season [<a href="#rid5">5,31</a>]. In addition, there is a smaller increase in incidence in December, during the middle of the dry season [<a href="#rid31">31</a>].</p><p>Lassa virus infection poses a significant healthcare burden in high-incidence regions. In one study examining admissions to two hospitals in Sierra Leone, Lassa fever cases resulted in 10 to 16 percent of medical admissions and 30 percent of all deaths [<a href="#rid32">32</a>].</p><p>A large increase in Lassa fever cases occurred in Nigeria between December 2017 and May 2018; there were more than 600 laboratory-confirmed cases with an estimated case-fatality rate of 27 percent [<a href="#rid33">33</a>]. This outbreak raised concern among public health officials regarding emergence of a new or more virulent Lassa virus strain. In a comparison of Lassa virus genomes from more than 100 patients from the 2018 outbreak and more than 90 patients from the two prior seasons, the 2018 Lassa genomes were found to represent a diverse range of viruses previously observed in Nigeria (rather than a single dominant strain), suggesting no clear association between the outbreak and a single virus strain [<a href="#rid34">34</a>]. The reason for the outbreak remains unknown; it may reflect changes in the rodent reservoir population or improved surveillance and heightened public awareness. Since 2018, an increased number of cases have continued to be seen with over 1000 cases in 2020 and 2022 [<a href="#rid33">33,35</a>].</p><p>Imported cases of Lassa fever have been described among returned travelers, with a relatively high case fatality rate (&gt;30 percent) [<a href="#rid36">36,37</a>]. </p><p class="headingAnchor" id="H2399476401"><span class="h2">Transmission</span><span class="headingEndMark"> — </span>Modes of Lassa fever transmission include rodent contact and person-to-person contact.</p><p class="headingAnchor" id="H1464461432"><span class="h3">Rodent contact</span><span class="headingEndMark"> — </span>The primary mode of transmission to humans is via exposure to infected <em>Mastomys</em> rodents; this may occur via direct contact with rodent urine and feces, inhalation of aerosolized rodent excretions, or consumption of infected rodents as a food source [<a href="#rid4">4,13</a>].</p><p><em>Mastomys</em> rodent infestation is associated with households built of poor-quality materials, such as crumbling mud, which facilitates rodent burrows [<a href="#rid38">38</a>]. In one study, residences of patients with Lassa virus infection were 10 times more likely to be infested with <em>Mastomys</em> rodents than residences with no cases [<a href="#rid39">39</a>].</p><p>Individuals with a history of routine <em>Mastomys</em> rodent consumption are more than twice as likely to have serologic evidence of Lassa virus infection as individuals who do not consume the rodents [<a href="#rid40">40</a>]. In addition, <em>Mastomys</em> rodent consumption is associated with a fourfold increase in deafness, a common sequela of Lassa fever infection. (See <a class="local">'Clinical manifestations'</a> below.)</p><p class="headingAnchor" id="H504168341"><span class="h3">Person-to-person</span><span class="headingEndMark"> — </span>Person-to-person transmission may occur after exposure to Lassa virus in the blood, urine, feces, or other bodily secretions of an infected individual [<a href="#rid41">41-43</a>]. Lassa virus infection is not thought to spread through casual contact (such as hugging, shaking hands, or sitting near someone) [<a href="#rid44">44</a>]. Individuals with Lassa virus infection are not believed to be contagious prior to onset of symptoms.</p><p>Individuals in close contact with patients, including healthcare workers, are at risk for transmission of infection via body fluids and airborne droplets in the absence of appropriate protective measures [<a href="#rid11">11,28,41,45</a>]. Nosocomial outbreaks of Lassa fever have been described, and enhanced precautions must be taken when caring for patients with suspected or confirmed Lassa fever [<a href="#rid10">10,11,46,47</a>]. (See <a class="local">'Prevention'</a> below.)</p><p>Risk for person-to-person transmission of Lassa virus persists after recovery; the virus is shed in the urine for three to nine weeks and in the semen for up to three months [<a href="#rid5">5</a>]. Sexual transmission of Lassa fever infection during convalescence has been described [<a href="#rid48">48</a>]. (See <a class="local">'Sexual transmission'</a> below.)</p><p class="headingAnchor" id="H33858528"><span class="h1">PATHOGENESIS</span><span class="headingEndMark"> — </span>Infection with Lassa virus generally occurs via the nasopharyngeal mucosa, where it infects dendritic cells, monocytes, and macrophages [<a href="#rid49">49-51</a>]. Subsequently, the virus spreads to regional lymph nodes before disseminating to virtually all tissues. </p><p>Inflammatory cell infiltrate of infected organs tends to be minimal [<a href="#rid51">51,52</a>]; necrosis can occur, particularly in the liver and spleen [<a href="#rid50">50-52</a>]. Hepatic necrosis can be significant, involving up to 40 percent of hepatocytes [<a href="#rid51">51,52</a>]. Splenic necrosis, adrenocortical and pituitary necrosis, interstitial myocarditis, alveolar edema, and renal tubular injury are also common [<a href="#rid6">6,51-53</a>]. Viral infection of endothelial cells in all major organs has been described [<a href="#rid52">52</a>].</p><p>Severe disease appears to result from vascular instability and impaired hemostasis [<a href="#rid54">54</a>]. Lassa virus stimulates macrophages and dendritic cells to release soluble mediators resulting in the endothelial dysfunction, insufficient effective circulating intravascular volume, and multiorgan failure [<a href="#rid54">54-57</a>]. This results in pleural effusions and pulmonary edema, ascites, and hemorrhagic manifestations of the gastrointestinal mucosa [<a href="#rid6">6,58</a>]. Hemorrhage has also been associated with a circulating inhibitor of platelet aggregation and thrombocytopenia [<a href="#rid59">59</a>].</p><p>Among survivors, Lassa virus levels peak between days 4 and 9 of illness, and serum viral RNA can be detected for up to three weeks after recovery [<a href="#rid41">41,60,61</a>]. Cell-mediated immunity is predominantly responsible for survival [<a href="#rid55">55,62-64</a>]. Neutralizing antibodies appear after recovery [<a href="#rid41">41,48</a>].</p><p>In fatal cases, the cellular response to Lassa virus infection appears to be weak. Lassa virus does not activate monocytes and macrophages to secrete proinflammatory cytokines among fatal cases [<a href="#rid65">65,66</a>]. This virus-induced immunosuppression may allow the Lassa virus to replicate unchecked in fatal cases.</p><p class="headingAnchor" id="H1876040219"><span class="h1">CLINICAL MANIFESTATIONS</span></p><p class="headingAnchor" id="H785382394"><span class="h2">Overview</span><span class="headingEndMark"> — </span>Lassa virus infection is associated with a broad spectrum of clinical manifestations [<a href="#rid4">4</a>]. The incubation period is one to three weeks [<a href="#rid6">6,27,32,67-69</a>]. Individuals with Lassa virus infection are not believed to be contagious prior to onset of symptoms. Most infected individuals (approximately 80 percent) have mild symptoms (low-grade fever, malaise, and headache) and may not seek medical attention.</p><p>Disease progresses to more serious signs and symptoms in approximately 20 percent of patients; these include pharyngitis, cough, nausea, vomiting, diarrhea, myalgias, retrosternal chest pain, back pain, and abdominal pain [<a href="#rid70">70</a>]. In severe cases, facial swelling, pulmonary edema, bleeding (from the mouth, nose, vagina, or gastrointestinal tract), and hypotension may develop. Proteinuria may be noted. Shock, seizures, tremor, disorientation, and coma may be seen in the later stages.</p><p>The most common complication of Lassa fever is deafness, which occurs in up to one-third of patients and may develop in the setting of mild or severe illness [<a href="#rid32">32,71-74</a>]. Onset of hearing loss may occur during acute illness or during convalescence. Hearing may improve after one to three months in approximately half of cases.</p><p>Patients who recover generally begin to improve after 8 to 10 days of symptom onset. Some patients have signs of improvement followed by relapse of fever with pulmonary edema.</p><p>Poor prognostic factors include the presence of vomiting, sore throat, tachypnea, bleeding, and diarrhea [<a href="#rid6">6,32,41,48</a>]. High-level viremia at presentation (determined by measurement of serum antigen or genomic copies) has been correlated with increased mortality [<a href="#rid41">41,75,76</a>].</p><p>Death usually occurs within two weeks after onset of symptoms in fatal cases. Approximately 1 percent of Lassa virus infections result in death; among hospitalized patients, case-fatality rates range from 15 to 30 percent [<a href="#rid31">31,32</a>]. Mortality rates can be high (≥50 percent) in the setting of nosocomial outbreaks [<a href="#rid47">47</a>].</p><p class="headingAnchor" id="H1880424331"><span class="h3">Signs and symptoms by organ system</span><span class="headingEndMark"> — </span>Signs and symptoms are summarized by organ system below.</p><p class="bulletIndent1"><span class="glyph">●</span>Central nervous system – Sensorineural deafness occurs in up to one-third of patients, and it becomes permanent in approximately 18 percent. In severe cases of Lassa virus infection, disorientation, ataxia, and seizures can occur in as many as one-third of patients [<a href="#rid27">27,32,77</a>]. Encephalopathy has been described [<a href="#rid78">78</a>]. It is not clear whether these clinical manifestations reflect direct viral invasion of the central nervous system, an immune response, or metabolic disturbances [<a href="#rid79">79</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Head and neck – Cervical lymphadenopathy is a common symptom of Lassa virus infection. Pharyngitis and bilateral conjunctivitis occur in 70 and 40 percent of cases, respectively [<a href="#rid31">31,32,51</a>]. Edema of the head and neck is a distinctive feature of Lassa fever and is seen in approximately 30 percent of hospitalized cases.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Pulmonary – A dry cough may occur. Pulmonary edema and pleural effusions may develop late in the course of disease [<a href="#rid80">80,81</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Cardiovascular – Retrosternal chest pain occurs in approximately 70 percent of patients [<a href="#rid32">32</a>]. In one review of electrocardiograms from 32 patients with Lassa fever, 75 percent were abnormal; nonspecific ST and T wave changes were observed in 69 percent of cases [<a href="#rid82">82</a>]. Myocarditis has been observed in some cases of Lassa fever [<a href="#rid6">6,80,81</a>]; nonhuman primate studies have demonstrated that Lassa virus is myocardiotropic, resulting in pulmonary and coronary arteritis as well as perivascular myocarditis [<a href="#rid51">51</a>]. Pericardial effusions have been described infrequently [<a href="#rid80">80</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Gastrointestinal – Diarrhea and vomiting are common [<a href="#rid31">31,53,72</a>]. In severe cases, abdominal pain is common, likely due to accumulation of fluid in the abdominal cavity [<a href="#rid51">51</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Renal – Acute renal failure occurs commonly among patients hospitalized with Lassa fever; in one series, it was observed in 28 percent of cases [<a href="#rid77">77</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Rash – A maculopapular rash may appear on the thorax, face, and upper extremities in less than 5 percent of cases [<a href="#rid27">27</a>]; it may be difficult to see in darker-skinned individuals.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Hemorrhage – Overt hemorrhage occurs in fewer than 20 percent of patients warranting hospitalization [<a href="#rid27">27,32</a>]. Manifestations generally consist of blood oozing from the mouth, nose, vagina, gastrointestinal tract, and cannulation and injection sites. Occasionally, rectal bleeding occurs. The hemorrhagic component of severe Lassa fever cases appears to be due to endovascular leakage as well as inhibition of platelet aggregation [<a href="#rid83">83</a>]. However, disseminated intravascular coagulation is generally not observed [<a href="#rid84">84</a>].</p><p></p><p class="headingAnchor" id="H1266652650"><span class="h3">Pregnancy</span><span class="headingEndMark"> — </span>Lassa fever is especially severe in late pregnancy; maternal death and/or fetal loss occur in more than 80 percent of cases during the third trimester [<a href="#rid85">85</a>]. Pregnant women are more likely to have severe illness due to Lassa virus infection than nonpregnant women. In a meta-analysis including 276 pregnant women with Lassa fever, the case fatality rate was 34 percent; compared with nonpregnant patients, the relative risk of death for pregnant women was 2.86 [<a href="#rid86">86</a>]. </p><p>A "swollen baby syndrome" has been described among babies born to women infected during the third trimester; it consists of anasarca, abdominal distension, and bleeding [<a href="#rid87">87</a>]. The fetal case fatality rate is 61.5 to 100 percent [<a href="#rid86">86,87</a>]. </p><p class="headingAnchor" id="H1547649939"><span class="h2">Laboratory findings</span><span class="headingEndMark"> — </span>Laboratory findings associated with Lassa fever infection include:</p><p class="bulletIndent1"><span class="glyph">●</span>Leukopenia – Early in the course of infection, patients generally have a mild leukopenia with a predominant lymphopenia [<a href="#rid32">32,59,67-69,88,89</a>]. Subsequently, patients may develop a leukocytosis with neutrophilia.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Thrombocytopenia – Mild thrombocytopenia has been observed; the platelet count is rarely below 100,000/microL [<a href="#rid83">83</a>]. Patients with severe Lassa fever have significantly decreased platelet aggregation, which may be due to an inhibitor responsible for decreased platelet function [<a href="#rid54">54,59,83</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Elevated transaminases and amylase – Both alanine aminotransferase (ALT) and aspartate aminotransferase (AST) are elevated; AST is usually significantly greater than ALT, often at a ratio of 10:1 [<a href="#rid88">88,90</a>]. AST ≥120 international units (IU)/L at the time of presentation has been associated with increased mortality risk [<a href="#rid77">77</a>]. Amylase is frequently elevated as well.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Coagulation abnormalities – Prothrombin and partial thromboplastic times are usually normal even in severely ill patients [<a href="#rid84">84</a>]. Disseminated intravascular coagulation does not play a significant role in Lassa fever disease (in contrast with some other viral hemorrhagic fevers such as Ebola virus disease).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Renal abnormalities – Renal insufficiency has been associated with increased risk of mortality due to Lassa fever [<a href="#rid77">77,91</a>]. Proteinuria is common (57 percent of patients in one study) [<a href="#rid32">32</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Spinal fluid findings – Lassa virus has been isolated from the spinal fluid in a small number of cases [<a href="#rid41">41,71,92</a>]. Spinal fluid analysis in patients with Lassa fever has demonstrated mild to moderate pleocytosis.</p><p></p><p>Lassa virus can be transmitted via blood and other body fluids; therefore, when possible, routine laboratory testing (such as complete blood cell counts and metabolic panels) should be done via point-of-care equipment rather than in the hospital laboratory. (See <a class="local">'Prevention'</a> below.)</p><p class="headingAnchor" id="H527072567"><span class="h1">DIAGNOSIS</span><span class="headingEndMark"> — </span>The diagnosis of Lassa fever should be suspected in individuals with suggestive signs and symptoms (these include fever, malaise, headache, pharyngitis, cough, nausea, vomiting, diarrhea, myalgia, chest pain, or hearing loss) in the setting of relevant epidemiologic exposure (residence in or travel to an endemic area with exposure to <em>Mastomys</em> rodents and/or symptomatic individuals with known or suspected Lassa fever in the past three months, or unprotected sexual contact with a person who meets these criteria). Patients being evaluated for Lassa fever should be isolated. (See <a class="local">'Prevention'</a> below.)</p><p>The World Health Organization case definition for suspected acute Lassa fever is summarized in the  (<a class="graphic graphic_table graphicRef109492" href="/z/d/graphic/109492.html" rel="external">table 1</a>). Administration of empiric treatment with <a class="drug drug_general" data-topicid="9860" href="/z/d/drug information/9860.html" rel="external">ribavirin</a> is reasonable for patients in endemic areas with symptoms strongly suggestive of Lassa fever, prior to diagnostic confirmation. (See <a class="local">'Treatment'</a> below.)</p><p>The preferred test for diagnosis of Lassa fever is serum reverse-transcription polymerase chain reaction; however, this is rarely used in regions where Lassa fever is endemic because it requires expensive equipment and technical expertise [<a href="#rid60">60,61,93,94</a>]. In addition, the genetic heterogeneity within and between the lineages makes the molecular diagnosis of Lassa virus difficult [<a href="#rid95">95,96</a>].</p><p>The diagnosis of Lassa fever in some endemic regions may be established via serum enzyme-linked immunosorbent serologic assay, which can detect immunoglobulin (Ig)M and IgG antibodies and Lassa antigen [<a href="#rid97">97</a>]. Antigen is typically detectable at the time of symptom onset. However, if initial testing is negative, but a high index of suspicion for Lassa fever remains, the test should be repeated in 24 to 48 hours. Serum IgM is detectable 10 to 21 days after symptom onset; serum IgG is detectable approximately 21 days after symptom onset [<a href="#rid48">48,76,98</a>]. In one study, Lassa virus serology had sensitivity and specificity of 88 and 90 percent, respectively [<a href="#rid48">48</a>]. There is variation among Lassa virus lineages, and some assays may not have equal sensitivity for each lineage [<a href="#rid99">99</a>]. In addition, there is some cross-reactivity between Lassa fever virus, lymphocytic choriomeningitis virus, and New World arenaviruses such as Tacaribe virus [<a href="#rid13">13</a>]. Enzyme-linked immunosorbent serologic and antigen assays take 4 to 18 hours to perform depending on the individual platform used.</p><p>Lassa virus may be cultured from blood, urine, or throat washings, but these are not routine clinical diagnostic tools, and culture should be performed only in high-containment laboratories. A postmortem diagnosis may be established via immunohistochemistry performed on formalin-fixed tissue specimens.</p><p>Diagnostic evaluation of patients with suspected Lassa fever infection should also include diagnostic testing for malaria, blood cultures, and evaluation for other infections as described in the following section. (See <a class="local">'Differential diagnosis'</a> below.)</p><p class="headingAnchor" id="H4046616594"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>The differential diagnosis of Lassa fever virus infection includes [<a href="#rid100">100</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Other viral hemorrhagic fevers:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Ebola and Marburg virus – Both Ebola and Marburg virus are causes of viral hemorrhagic fevers endemic to West Africa with symptoms and signs similar to those caused by Lassa virus. The diagnosis of Ebola or Marburg virus is established via reverse-transcription polymerase chain reaction (RT-PCR) in blood or other body fluids. (See  <a class="medical medical_review" href="/z/d/html/3022.html" rel="external">"Clinical manifestations and diagnosis of Ebola virus disease"</a> and  <a class="medical medical_review" href="/z/d/html/98084.html" rel="external">"Marburg virus"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Dengue – Dengue is an acute febrile illness accompanied by fever, headache, retro-orbital pain, and marked muscle and joint pain. Hemorrhagic manifestations and thrombocytopenia can also occur. The virus is transmitted by <em>Aedes aegypti</em> mosquitoes, which have broad epidemiologic distribution. The diagnosis of dengue fever is established via serologic testing. (See  <a class="medical medical_review" href="/z/d/html/3025.html" rel="external">"Dengue virus infection: Clinical manifestations and diagnosis"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Crimean-Congo hemorrhagic fever – Crimean-Congo hemorrhagic fever (CCHF) is a zoonotic disease caused by a virus transmitted by ticks and characterized by fever and hemorrhage; it is endemic in parts of Africa, the Middle East, Asia, and southeastern Europe. The diagnosis is established via RT-PCR or serology. (See  <a class="medical medical_review" href="/z/d/html/102363.html" rel="external">"Crimean-Congo hemorrhagic fever"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Yellow fever – Yellow fever is a mosquito-borne viral hemorrhagic fever endemic to tropical regions of South America and sub-Saharan Africa. It is characterized by acute infection with nonspecific symptoms, followed by a period of remission and a subsequent episode of illness with hepatic and renal dysfunction. The diagnosis is established via serology or RT-PCR. (See  <a class="medical medical_review" href="/z/d/html/3032.html" rel="external">"Yellow fever: Epidemiology, clinical manifestations, and diagnosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Malaria – Malaria is the most common diagnosis in ill travelers returning from West Africa; it is a mosquito-borne illness with nonspecific clinical manifestations including fever, malaise, headache, anorexia, nausea, vomiting, abdominal pain, diarrhea, arthralgias, and myalgias. The diagnosis is established via rapid diagnostic testing or blood smear. (See  <a class="medical medical_review" href="/z/d/html/5709.html" rel="external">"Malaria: Clinical manifestations and diagnosis in nonpregnant adults and children"</a> and  <a class="medical medical_review" href="/z/d/html/5707.html" rel="external">"Laboratory tools for diagnosis of malaria"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Typhoid – Typhoid fever is common in areas where Lassa fever is endemic. Clinical manifestations of typhoid fever include abdominal pain, fever, and chills; classic manifestations include relative bradycardia, pulse-temperature dissociation, and "rose spots" (faint salmon-colored macules on the trunk and abdomen). Typhoid is diagnosed by identifying the organism in blood cultures. (See  <a class="medical medical_review" href="/z/d/html/2708.html" rel="external">"Enteric (typhoid and paratyphoid) fever: Epidemiology, clinical manifestations, and diagnosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Travelers' diarrhea – Travelers' diarrhea typically occurs during travel or within 10 days after returning; clinical manifestations include watery diarrhea, malaise, anorexia, and abdominal cramps. It is important to differentiate patients with travelers' diarrhea from those with a more systemic syndrome associated with other symptoms. The diagnosis of travelers' diarrhea is established via stool and/or blood cultures. (See  <a class="medical medical_review" href="/z/d/html/99648.html" rel="external">"Travelers' diarrhea: Treatment and prevention"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Sepsis due to bacterial infection – Patients with sepsis due to bacterial infection typically present with fever, hypotension, disorientation, and/or respiratory failure. The diagnosis is established via blood culture. (See  <a class="medical medical_review" href="/z/d/html/3149.html" rel="external">"Gram-negative bacillary bacteremia in adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Influenza – Clinical manifestations of influenza and Lassa fever include fever, headache, myalgias, and malaise; rhinorrhea is commonly associated with influenza but does not generally occur in the setting of Lassa fever infection. Influenza can occur year-round in the tropics; the preferred diagnostic test is RT-PCR. (See  <a class="medical medical_review" href="/z/d/html/7004.html" rel="external">"Seasonal influenza in adults: Clinical manifestations and diagnosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Streptococcal pharyngitis – Clinical manifestations of streptococcal pharyngitis include sore throat, particularly when swallowing; fever is often present and may occur in association with headache or malaise. Patients may note anterior neck pain related to lymphadenopathy. The diagnosis is established via throat culture or rapid antigen testing. (See  <a class="medical medical_review" href="/z/d/html/6867.html" rel="external">"Evaluation of acute pharyngitis in adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Meningococcal meningitis – Clinical manifestations of meningococcal disease include fever, headache, nausea, vomiting, and myalgias. A purpuric rash may occur. The diagnosis is established via analysis of cerebrospinal fluid or blood cultures. (See  <a class="medical medical_review" href="/z/d/html/1300.html" rel="external">"Clinical manifestations of meningococcal infection"</a> and  <a class="medical medical_review" href="/z/d/html/1281.html" rel="external">"Diagnosis of meningococcal infection"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Leptospirosis – Clinical manifestations of leptospirosis include abrupt onset of fever, rigors, myalgias, and headache. Conjunctival suffusion is a distinguishing feature. Animal reservoirs include rodents and domestic animals. The diagnosis is established via serologic testing. (See  <a class="medical medical_review" href="/z/d/html/5527.html" rel="external">"Leptospirosis: Epidemiology, microbiology, clinical manifestations, and diagnosis"</a>.)</p><p></p><p class="headingAnchor" id="H4031885754"><span class="h1">TREATMENT</span></p><p class="headingAnchor" id="H2372251981"><span class="h2">Supportive care</span><span class="headingEndMark"> — </span>Treatment of Lassa fever consists primarily of supportive care, including maintenance of oxygenation and blood pressure. Fluid replacement is important although care must be taken to avoid volume overload due to the risk of capillary leak and renal dysfunction. <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">Aspirin</a> and nonsteroidal anti-inflammatory drugs should be avoided because these agents can adversely affect clotting. </p><p class="headingAnchor" id="H1781982745"><span class="h2">Ribavirin</span><span class="headingEndMark"> — </span>In addition to supportive care, we suggest administering <a class="drug drug_general" data-topicid="9860" href="/z/d/drug information/9860.html" rel="external">ribavirin</a> for all symptomatic patients with a confirmed diagnosis of Lassa fever. Empiric treatment with ribavirin is reasonable for patients in endemic areas with symptoms strongly suggestive of the illness. Our recommendations are generally in agreement with expert guidelines [<a href="#rid101">101</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Timing</strong> – <a class="drug drug_general" data-topicid="9860" href="/z/d/drug information/9860.html" rel="external">Ribavirin</a> has been reported to be most effective when given within the first six days after onset of symptoms [<a href="#rid90">90</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dose</strong> – Intravenous (IV) administration is preferred because higher serum concentrations can be achieved than with oral formulations. Oral <a class="drug drug_general" data-topicid="9860" href="/z/d/drug information/9860.html" rel="external">ribavirin</a> is acceptable if IV ribavirin is not available [<a href="#rid49">49,90,102</a>]. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>IV <a class="drug drug_general" data-topicid="9860" href="/z/d/drug information/9860.html" rel="external">ribavirin</a>: Loading dose 30 mg/kg (maximum 2 g), followed by 15 mg/kg (maximum 1 g) every six hours for four days, followed by 7.5 mg/kg (maximum 500 mg) every eight hours for six days [<a href="#rid42">42</a>]. </p><p></p><p class="bulletIndent2">An alternative dosing strategy (100 mg/kg on day 1, 25 mg/kg on days 2 to 5, and 12.5 mg/kg on days 6 to 10) is used at a single institution, and efficacy and safety data are not available [<a href="#rid103">103</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Oral <a class="drug drug_general" data-topicid="9860" href="/z/d/drug information/9860.html" rel="external">ribavirin</a>: 35 mg/kg (maximum 2.5 g), followed by 15 mg/kg (maximum 1 g) every six hours for four days, followed by 15 mg/kg (maximum 1 g) every eight hours for six days.</p><p></p><p class="bulletIndent2">The optimal oral dosing regimen is unknown. Given the lower serum levels of oral <a class="drug drug_general" data-topicid="9860" href="/z/d/drug information/9860.html" rel="external">ribavirin</a> compared with IV ribavirin, it is reasonable to use higher doses (as summarized above), although no pharmacologic or efficacy data are available.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Side effects</strong> – Side effects include hemolytic anemia, which is reversible, and rigors during infusion [<a href="#rid90">90,104</a>]. Rigors can be ameliorated by judicious prehydration and pretreatment with <a class="drug drug_general" data-topicid="9369" href="/z/d/drug information/9369.html" rel="external">diphenhydramine</a> (25 to 50 mg orally or IV) administered 30 minutes prior to <a class="drug drug_general" data-topicid="9860" href="/z/d/drug information/9860.html" rel="external">ribavirin</a>. </p><p></p><p class="bulletIndent1">We recommend monitoring renal function and hemoglobin concentration daily during treatment. If symptomatic anemia develops, transfusion of blood products should be considered. If renal insufficiency occurs, <a class="drug drug_general" data-topicid="9860" href="/z/d/drug information/9860.html" rel="external">ribavirin</a> dosages may require adjustment based on the specific manufacturer's recommendations. Ribavirin-associated hemolytic anemia has been found to worsen underlying cardiac disease and has sometimes lead to myocardial infarction so caution is necessary when deciding whether to administer it to patients with known cardiac disease. </p><p></p><p>Our recommendations are based on a single report of small trials in patients in Sierra Leone with confirmed Lassa fever and serum aspartate aminotransferase levels (AST) ≥150 international units (IU)/L at the time of admission in the late 1970s and early 1980s [<a href="#rid90">90</a>]. IV or oral <a class="drug drug_general" data-topicid="9860" href="/z/d/drug information/9860.html" rel="external">ribavirin</a> for 10 days resulted in lower case fatality rates than no treatment (19, 14, and 55 percent, respectively) and the case fatality rate was lowest (5 percent) in patients who received IV ribavirin within the first six days of illness. </p><p>After publication, the data set used in the Sierra Leone study was re-evaluated, which led some experts to question the validity of the findings [<a href="#rid105">105-109</a>]. Additionally, systematic reviews, a meta-analysis, and post-hoc analyses of the Sierra Leone dataset have suggested that <a class="drug drug_general" data-topicid="9860" href="/z/d/drug information/9860.html" rel="external">ribavirin</a> may actually increase mortality in patients with an AST &lt;150 IU/L, although these analyses mostly rely on the Sierra Leone publication. Nonetheless, based on these concerns, some experts withhold ribavirin for individual patients with mild to no symptoms and an AST &lt;150 IU/L.</p><p>The specific mechanism of action of <a class="drug drug_general" data-topicid="9860" href="/z/d/drug information/9860.html" rel="external">ribavirin</a> in the treatment of Lassa fever is unclear. Reduction in markers of cell damage suggests that it may have an anti-inflammatory effect, whereas pharmacokinetic studies question its anti-viral efficacy at recommended dosages [<a href="#rid110">110</a>]. </p><p><a class="drug drug_general" data-topicid="9860" href="/z/d/drug information/9860.html" rel="external">Ribavirin</a> may be difficult to obtain in certain regions and shortages have been known to occur. Under these circumstances, we recommend seeking out clinical trials utilizing other antivirals. If direct participation is not possible, we recommend requesting compassionate use authorization from the manufacturer. </p><p class="headingAnchor" id="H3340111839"><span class="h2">Empiric treatment for other infections</span><span class="headingEndMark"> — </span>The patient should be evaluated for other infections as described above, including malaria, typhoid, and secondary bacterial infection; antimicrobial therapy should be tailored accordingly. If malaria cannot be ruled out in a timely manner, empiric treatment for malaria is warranted. (See <a class="local">'Differential diagnosis'</a> above and  <a class="medical medical_review" href="/z/d/html/5704.html" rel="external">"Treatment of uncomplicated falciparum malaria in nonpregnant adults and children"</a> and  <a class="medical medical_review" href="/z/d/html/5667.html" rel="external">"Treatment of severe malaria"</a>.)</p><p class="headingAnchor" id="H902022813"><span class="h1">MONITORING RESPONSE</span><span class="headingEndMark"> — </span>Improvement manifests as resolution of fever, transaminitis, and other clinical manifestations and generally occurs 8 to 10 days after onset of symptoms.</p><p>We suggest monitoring serum Lassa antigen levels to monitor response (we check it on days 2, 3, 4, 7, and 10 of illness). In our experience, antigenemia almost always resolves by day 10.</p><p class="headingAnchor" id="H2995900830"><span class="h1">PREVENTION</span><span class="headingEndMark"> — </span>Thus far, there is no vaccine for prevention of Lassa virus infection [<a href="#rid111">111</a>]. Preventive measures include avoiding <em>Mastomys</em> rodents and minimizing risk of person-to-person transmission.</p><p>Post-exposure prophylaxis is warranted for contacts of patients with known or suspected Lassa fever infection who have risk factors for transmission; this is discussed further below.</p><p class="headingAnchor" id="H2562889944"><span class="h2">Avoiding rodents</span><span class="headingEndMark"> — </span>Residents of and travelers to areas where <em>Mastomys</em> rodents are endemic should store food in rodent-proof containers, trap rodents in and around homes, and avoid using rodents as a food source [<a href="#rid44">44</a>].</p><p class="headingAnchor" id="H685095264"><span class="h2">Minimizing risk of person-to-person transmission</span><span class="headingEndMark"> — </span>Patients with known or suspected Lassa fever should be managed in healthcare facilities whenever possible; community-based care should be avoided to minimize the risk of person-to-person transmission. Patients with signs and symptoms of infection should be considered contagious, even if the clinical manifestations are mild.</p><p class="headingAnchor" id="H1725793402"><span class="h3">Infection control</span><span class="headingEndMark"> — </span>The approach to infection control for preventing transmission of Lassa fever virus is similar to the approach for preventing transmission of other viral hemorrhagic fevers such as Ebola virus disease [<a href="#rid112">112</a>]. (See  <a class="medical medical_review" href="/z/d/html/97985.html" rel="external">"Treatment and prevention of Ebola virus disease", section on 'Infection control precautions during acute illness'</a>.)</p><p>Patients being evaluated or treated for Lassa fever infection in healthcare facilities should be isolated. Handwashing is of the utmost importance, and care should include enhanced precautions (including standard, contact, and droplet precautions as well as correct use of appropriate personal protective equipment [PPE]). PPE consists of gloves, gown, mask, goggles, and foot coverings; the equipment should be put on and removed under the supervision of a trained monitor to minimize risk of contamination. (See  <a class="medical medical_review" href="/z/d/html/4042.html" rel="external">"Infection prevention: Precautions for preventing transmission of infection"</a>.)</p><p>Blood and body fluid specimens from patients with suspected Lassa fever infection should be considered highly infectious and handled with extreme caution. Routine laboratory tests (such as complete blood cell counts and metabolic panels) should be done via point-of-care tools rather than in the hospital laboratory. Medical equipment should be sterilized, and soiled linens should be handled as potentially hazardous material.</p><p>The body of a deceased patient should not be returned to family members; it should be placed in a sealed body bag and trained personnel in PPE should handle and bury the body. Family members should not open the body bag or clean the body of a deceased patient with Lassa fever.</p><p class="headingAnchor" id="H35866001"><span class="h3">Sexual transmission</span><span class="headingEndMark"> — </span>Sexual transmission of Lassa fever infection during convalescence has been described [<a href="#rid48">48</a>]. Individuals should wait at least three months following resolution of Lassa fever infection before unprotected sex.</p><p class="headingAnchor" id="H2392452565"><span class="h2">Post-exposure prophylaxis</span><span class="headingEndMark"> — </span>Post-exposure prophylaxis (PEP) is warranted for contacts of patients with known or suspected Lassa fever infection with risk factors for transmission; these include penetrating needle stick injury, exposure of mucous membranes or broken skin to blood or body fluids, and participation in procedures involving exposure to bodily fluids or respiratory secretions without use of PPE [<a href="#rid113">113</a>].</p><p>Post-exposure prophylaxis consists of <a class="drug drug_general" data-topicid="9860" href="/z/d/drug information/9860.html" rel="external">ribavirin</a> administered via 35 mg/kg orally as a loading dose (maximum dose 2.5 g), followed by 15 mg/kg orally (maximum dose 1 g) every eight hours for 10 days [<a href="#rid90">90,114-117</a>].</p><p>Patients receiving post-exposure prophylaxis should be monitored closely for 21 days; those who develop fever (temperature ≥38.3°C) should begin treatment with intravenous <a class="drug drug_general" data-topicid="9860" href="/z/d/drug information/9860.html" rel="external">ribavirin</a> while awaiting diagnostic testing for Lassa fever infection. (See <a class="local">'Treatment'</a> above.)</p><p class="headingAnchor" id="H2196727391"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Epidemiology</strong> – Lassa fever is a viral hemorrhagic fever caused by Lassa virus that is endemic to West Africa. Approximately 300,000 cases and 5000 deaths occur annually. (See <a class="local">'Geography'</a> above.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Transmission</strong> – The primary mode of transmission is via exposure to infected <em>Mastomys</em> rodents by direct contact with rodent urine or feces, inhalation of aerosolized rodent excretions, or consumption of infected rodents as a food source. (See <a class="local">'Rodent contact'</a> above.)</p><p></p><p class="bulletIndent1">Person-to-person transmission may occur after exposure to blood, urine, feces, or other bodily secretions from an infected individual. It is not spread through casual contact. (See <a class="local">'Person-to-person'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical manifestations</strong> – The incubation period is one to three weeks. Approximately 80 percent of cases are mild (low-grade fever, malaise, and headache). (See <a class="local">'Clinical manifestations'</a> above.)</p><p></p><p class="bulletIndent1">Clinical manifestations of more severe illness include pharyngitis, cough, nausea, vomiting, diarrhea, myalgias, retrosternal chest pain, back pain, and abdominal pain. Disease may progress to facial swelling, pulmonary edema, bleeding (from the mouth, nose, vagina, or gastrointestinal tract), and hypotension. (See <a class="local">'Clinical manifestations'</a> above.)</p><p></p><p class="bulletIndent1">Recovery typically begins 8 to 10 days after onset of symptoms. Overall mortality is approximately 1 percent; mortality for hospitalized patients is 15 to 30 percent. The most common complication among survivors is deafness, which occurs in up to one-third of patients. (See <a class="local">'Clinical manifestations'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical suspicion</strong> – Lassa fever should be suspected in individuals with typical signs and symptoms in the setting of potential rodent exposure in endemic areas or in individuals having had close contact with an infected person. The World Health Organization case definition is summarized in the table  (<a class="graphic graphic_table graphicRef109492" href="/z/d/graphic/109492.html" rel="external">table 1</a>). (See <a class="local">'Diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnostic tests</strong> – Diagnosis is usually established via detection of IgM and IgG antibodies and Lassa antigen in serum. Polymerase chain reaction (PCR) is preferred but is rarely used in regions where Lassa fever is endemic. (See <a class="local">'Diagnosis'</a> above.)</p><p></p><p class="bulletIndent1">Testing for other endemic infections, including malaria, typhoid, and secondary bacterial infections, should also be performed.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Supportive care</strong> – This is the mainstay of treatment, including maintenance of oxygenation and blood pressure. Fluid replacement is important, although care must be taken to avoid volume overload due to the risk of capillary leak and renal dysfunction. <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">Aspirin</a> and nonsteroidal anti-inflammatory drugs should be avoided because they can adversely affect clotting. (See <a class="local">'Treatment'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9860" href="/z/d/drug information/9860.html" rel="external">Ribavirin</a> – We suggest intravenous (IV) ribavirin for all patients (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). However, some experts withhold ribavirin for individual patients with mild to no symptoms and an aminotransferase level (AST) &lt;150 international units (IU)/L because of concern of toxicity. If IV ribavirin is not available, oral ribavirin is an alternative. Dosing is summarized above. (See <a class="local">'Treatment'</a> above.) </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Empiric treatment of other illnesses</strong> – If malaria cannot be ruled out in a timely manner, empiric treatment for malaria is warranted. (See  <a class="medical medical_review" href="/z/d/html/5704.html" rel="external">"Treatment of uncomplicated falciparum malaria in nonpregnant adults and children"</a> and  <a class="medical medical_review" href="/z/d/html/5667.html" rel="external">"Treatment of severe malaria"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prevention</strong> – Measures include avoiding rodents and isolation of potentially infected individuals. In healthcare facilities, enhanced precautions (standard, contact, and droplet) should be followed, and all blood and bodily fluids should be handled with extreme caution. (See <a class="local">'Prevention'</a> above and <a class="local">'Infection control'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Post-exposure prophylaxis</strong> – We suggest post-exposure prophylaxis (PEP) with oral <a class="drug drug_general" data-topicid="9860" href="/z/d/drug information/9860.html" rel="external">ribavirin</a> for close contacts of patients with known or suspected Lassa fever infection and risk factors for transmission (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). Risk factors include penetrating needle stick, exposure of mucous membranes or broken skin to blood or body fluids, and participation in procedures involving exposure to bodily fluids or respiratory secretions without use of personal protective equipment (PPE). (See <a class="local">'Post-exposure prophylaxis'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Bowen MD, Rollin PE, Ksiazek TG, et al. Genetic diversity among Lassa virus strains. J Virol 2000; 74:6992.</a></li><li><a class="nounderline abstract_t">Vieth S, Torda AE, Asper M, et al. Sequence analysis of L RNA of Lassa virus. Virology 2004; 318:153.</a></li><li><a class="nounderline abstract_t">Sevilla N, de la Torre JC. Arenavirus diversity and evolution: quasispecies in vivo. Curr Top Microbiol Immunol 2006; 299:315.</a></li><li><a class="nounderline abstract_t">McCormick JB, Webb PA, Krebs JW, et al. A prospective study of the epidemiology and ecology of Lassa fever. J Infect Dis 1987; 155:437.</a></li><li><a class="nounderline abstract_t">Richmond JK, Baglole DJ. Lassa fever: epidemiology, clinical features, and social consequences. BMJ 2003; 327:1271.</a></li><li><a class="nounderline abstract_t">Frame JD, Baldwin JM Jr, Gocke DJ, Troup JM. Lassa fever, a new virus disease of man from West Africa. I. Clinical description and pathological findings. Am J Trop Med Hyg 1970; 19:670.</a></li><li><a class="nounderline abstract_t">Troup JM, White HA, Fom AL, Carey DE. An outbreak of Lassa fever on the Jos plateau, Nigeria, in January-February 1970. A preliminary report. Am J Trop Med Hyg 1970; 19:695.</a></li><li><a class="nounderline abstract_t">Leifer E, Gocke DJ, Bourne H. Lassa fever, a new virus disease of man from West Africa. II. Report of a laboratory-acquired infection treated with plasma from a person recently recovered from the disease. Am J Trop Med Hyg 1970; 19:677.</a></li><li><a class="nounderline abstract_t">Buckley SM, Casals J, Downs WG. Isolation and antigenic characterization of Lassa virus. Nature 1970; 227:174.</a></li><li><a class="nounderline abstract_t">White HA. Lassa fever. A study of 23 hospital cases. Trans R Soc Trop Med Hyg 1972; 66:390.</a></li><li><a class="nounderline abstract_t">Carey DE, Kemp GE, White HA, et al. Lassa fever. Epidemiological aspects of the 1970 epidemic, Jos, Nigeria. Trans R Soc Trop Med Hyg 1972; 66:402.</a></li><li><a class="nounderline abstract_t">Bowen GS, Tomori O, Wulff H, et al. Lassa fever in Onitsha, East Central State, Nigeria in 1974. Bull World Health Organ 1975; 52:599.</a></li><li><a class="nounderline abstract_t">Monath TP, Newhouse VF, Kemp GE, et al. Lassa virus isolation from Mastomys natalensis rodents during an epidemic in Sierra Leone. Science 1974; 185:263.</a></li><li><a class="nounderline abstract_t">Darling RG, Catlett CL, Huebner KD, Jarrett DG. Threats in bioterrorism. I: CDC category A agents. Emerg Med Clin North Am 2002; 20:273.</a></li><li><a class="nounderline abstract_t">Monath TP, Casals J. Diagnosis of Lassa fever and the isolation and management of patients. Bull World Health Organ 1975; 52:707.</a></li><li><a class="nounderline abstract_t">Ogbu O, Ajuluchukwu E, Uneke CJ. Lassa fever in West African sub-region: an overview. J Vector Borne Dis 2007; 44:1.</a></li><li><a class="nounderline abstract_t">Fichet-Calvet E, Rogers DJ. Risk maps of Lassa fever in West Africa. PLoS Negl Trop Dis 2009; 3:e388.</a></li><li><a class="nounderline abstract_t">Günther S, Emmerich P, Laue T, et al. Imported lassa fever in Germany: molecular characterization of a new lassa virus strain. Emerg Infect Dis 2000; 6:466.</a></li><li><a class="nounderline abstract_t">Dzotsi EK, Ohene SA, Asiedu-Bekoe F, et al. The first cases of Lassa fever in Ghana. Ghana Med J 2012; 46:166.</a></li><li><a class="nounderline abstract_t">Atkin S, Anaraki S, Gothard P, et al. The first case of Lassa fever imported from Mali to the United Kingdom, February 2009. Euro Surveill 2009; 14.</a></li><li><a class="nounderline abstract_t">Safronetz D, Lopez JE, Sogoba N, et al. Detection of Lassa virus, Mali. Emerg Infect Dis 2010; 16:1123.</a></li><li><a class="nounderline abstract_t">Safronetz D, Sogoba N, Lopez JE, et al. Geographic distribution and genetic characterization of Lassa virus in sub-Saharan Mali. PLoS Negl Trop Dis 2013; 7:e2582.</a></li><li><a class="nounderline abstract_t">Sogoba N, Rosenke K, Adjemian J, et al. Lassa Virus Seroprevalence in Sibirilia Commune, Bougouni District, Southern Mali. Emerg Infect Dis 2016; 22:657.</a></li><li class="breakAll">ProMED-mail. Lassa fever - West Africa (16): Germany (North Rhine-Westphalia) local transmission 2016. http://www.promedmail.org/ (Accessed on March 29, 2016).</li><li class="breakAll">ProMED-mail. Lassa Fever, Imported - Germany Ex West Africa (05) 2000. http://www.promedmail.org/ (Accessed on March 29, 2016).</li><li class="breakAll">World Health Organization. WHO Disease Outbreak News. http://www.who.int/csr/don/19-february-2016-lassa-fever-benin/en/ (Accessed on February 29, 2016).</li><li><a class="nounderline abstract_t">Bausch DG, Demby AH, Coulibaly M, et al. Lassa fever in Guinea: I. Epidemiology of human disease and clinical observations. Vector Borne Zoonotic Dis 2001; 1:269.</a></li><li><a class="nounderline abstract_t">Kernéis S, Koivogui L, Magassouba N, et al. Prevalence and risk factors of Lassa seropositivity in inhabitants of the forest region of Guinea: a cross-sectional study. PLoS Negl Trop Dis 2009; 3:e548.</a></li><li><a class="nounderline abstract_t">Klempa B, Koulemou K, Auste B, et al. Seroepidemiological study reveals regional co-occurrence of Lassa- and Hantavirus antibodies in Upper Guinea, West Africa. Trop Med Int Health 2013; 18:366.</a></li><li><a class="nounderline abstract_t">Lukashevich IS, Clegg JC, Sidibe K. Lassa virus activity in Guinea: distribution of human antiviral antibody defined using enzyme-linked immunosorbent assay with recombinant antigen. J Med Virol 1993; 40:210.</a></li><li><a class="nounderline abstract_t">Shaffer JG, Grant DS, Schieffelin JS, et al. Lassa fever in post-conflict sierra leone. PLoS Negl Trop Dis 2014; 8:e2748.</a></li><li><a class="nounderline abstract_t">McCormick JB, King IJ, Webb PA, et al. A case-control study of the clinical diagnosis and course of Lassa fever. J Infect Dis 1987; 155:445.</a></li><li class="breakAll">National Disease Outbreak Dashboard 2006-2021 (All Diseases). Nigeria Centre for Disease Control and Prevention. Available at: https://www.ncdc.gov.ng/data. (Accessed on March 15, 2023).</li><li><a class="nounderline abstract_t">Siddle KJ, Eromon P, Barnes KG, et al. Genomic Analysis of Lassa Virus during an Increase in Cases in Nigeria in 2018. N Engl J Med 2018; 379:1745.</a></li><li><a class="nounderline abstract_t">Dalhat MM, Olayinka A, Meremikwu MM, et al. Epidemiological trends of Lassa fever in Nigeria, 2018-2021. PLoS One 2022; 17:e0279467.</a></li><li><a class="nounderline abstract_t">Kulkarni PA, Chew D, Youssef-Bessler M, et al. Case Report: Imported Case of Lassa Fever - New Jersey, May 2015. Am J Trop Med Hyg 2018; 99:1062.</a></li><li><a class="nounderline abstract_t">Kofman A, Choi MJ, Rollin PE. Lassa Fever in Travelers from West Africa, 1969-2016. Emerg Infect Dis 2019; 25:245.</a></li><li><a class="nounderline abstract_t">Bonner PC, Schmidt WP, Belmain SR, et al. Poor housing quality increases risk of rodent infestation and Lassa fever in refugee camps of Sierra Leone. Am J Trop Med Hyg 2007; 77:169.</a></li><li><a class="nounderline abstract_t">Keenlyside RA, McCormick JB, Webb PA, et al. Case-control study of Mastomys natalensis and humans in Lassa virus-infected households in Sierra Leone. Am J Trop Med Hyg 1983; 32:829.</a></li><li><a class="nounderline abstract_t">Ter Meulen J, Lukashevich I, Sidibe K, et al. Hunting of peridomestic rodents and consumption of their meat as possible risk factors for rodent-to-human transmission of Lassa virus in the Republic of Guinea. Am J Trop Med Hyg 1996; 55:661.</a></li><li><a class="nounderline abstract_t">Johnson KM, McCormick JB, Webb PA, et al. Clinical virology of Lassa fever in hospitalized patients. J Infect Dis 1987; 155:456.</a></li><li class="breakAll">World Health Organization. Clinical Management of Patients with Viral Haemorrhagic Fever: A Pocket Guide for the front-line health worker, 30 March 2014. WHO, Geneva 2014 http://apps.who.int/iris/bitstream/10665/130883/2/WHO_HSE_PED_AIP_14.05.pdf?ua=1 (Accessed on April 21, 2016).</li><li><a class="nounderline abstract_t">Lunkenheimer K, Hufert FT, Schmitz H. Detection of Lassa virus RNA in specimens from patients with Lassa fever by using the polymerase chain reaction. J Clin Microbiol 1990; 28:2689.</a></li><li class="breakAll">Centers for Disease Control and Prevention. What you need to know about Lassa Fever. https://www.cdc.gov/vhf/lassa/pdf/what-you-need-to-know-about-lassa-factsheet.pdf (Accessed on August 03, 2016).</li><li><a class="nounderline abstract_t">Stephenson EH, Larson EW, Dominik JW. Effect of environmental factors on aerosol-induced Lassa virus infection. J Med Virol 1984; 14:295.</a></li><li><a class="nounderline abstract_t">Monath TP, Mertens PE, Patton R, et al. A hospital epidemic of Lassa fever in Zorzor, Liberia, March-April 1972. Am J Trop Med Hyg 1973; 22:773.</a></li><li><a class="nounderline abstract_t">Fisher-Hoch SP, Tomori O, Nasidi A, et al. Review of cases of nosocomial Lassa fever in Nigeria: the high price of poor medical practice. BMJ 1995; 311:857.</a></li><li><a class="nounderline abstract_t">Bausch DG, Rollin PE, Demby AH, et al. Diagnosis and clinical virology of Lassa fever as evaluated by enzyme-linked immunosorbent assay, indirect fluorescent-antibody test, and virus isolation. J Clin Microbiol 2000; 38:2670.</a></li><li><a class="nounderline abstract_t">Jahrling PB, Hesse RA, Eddy GA, et al. Lassa virus infection of rhesus monkeys: pathogenesis and treatment with ribavirin. J Infect Dis 1980; 141:580.</a></li><li><a class="nounderline abstract_t">Callis RT, Jahrling PB, DePaoli A. Pathology of Lassa virus infection in the rhesus monkey. Am J Trop Med Hyg 1982; 31:1038.</a></li><li><a class="nounderline abstract_t">Walker DH, McCormick JB, Johnson KM, et al. Pathologic and virologic study of fatal Lassa fever in man. Am J Pathol 1982; 107:349.</a></li><li><a class="nounderline abstract_t">Shieh WJ, Demby A, Jones T, et al. Pathology and Pathogenesis of Lassa Fever: Novel Immunohistochemical Findings in Fatal Cases and Clinico-pathologic Correlation. Clin Infect Dis 2022; 74:1821.</a></li><li><a class="nounderline abstract_t">McCormick JB, Walker DH, King IJ, et al. Lassa virus hepatitis: a study of fatal Lassa fever in humans. Am J Trop Med Hyg 1986; 35:401.</a></li><li><a class="nounderline abstract_t">Horton LE, Cross RW, Hartnett JN, et al. Endotheliopathy and Platelet Dysfunction as Hallmarks of Fatal Lassa Fever. Emerg Infect Dis 2020; 26:2625.</a></li><li><a class="nounderline abstract_t">Peters CJ, Jahrling PB, Liu CT, et al. Experimental studies of arenaviral hemorrhagic fevers. Curr Top Microbiol Immunol 1987; 134:5.</a></li><li><a class="nounderline abstract_t">Roberts PJ, Cummins D, Bainton AL, et al. Plasma from patients with severe Lassa fever profoundly modulates f-met-leu-phe induced superoxide generation in neutrophils. Br J Haematol 1989; 73:152.</a></li><li><a class="nounderline abstract_t">Fennewald SM, Aronson JF, Zhang L, Herzog NK. Alterations in NF-kappaB and RBP-Jkappa by arenavirus infection of macrophages in vitro and in vivo. J Virol 2002; 76:1154.</a></li><li><a class="nounderline abstract_t">Edington GM, White HA. The pathology of Lassa fever. Trans R Soc Trop Med Hyg 1972; 66:381.</a></li><li><a class="nounderline abstract_t">Fisher-Hoch S, McCormick JB, Sasso D, Craven RB. Hematologic dysfunction in Lassa fever. J Med Virol 1988; 26:127.</a></li><li><a class="nounderline abstract_t">Demby AH, Chamberlain J, Brown DW, Clegg CS. Early diagnosis of Lassa fever by reverse transcription-PCR. J Clin Microbiol 1994; 32:2898.</a></li><li><a class="nounderline abstract_t">Trappier SG, Conaty AL, Farrar BB, et al. Evaluation of the polymerase chain reaction for diagnosis of Lassa virus infection. Am J Trop Med Hyg 1993; 49:214.</a></li><li><a class="nounderline abstract_t">Jahrling PB, Frame JD, Rhoderick JB, Monson MH. Endemic Lassa fever in Liberia. IV. Selection of optimally effective plasma for treatment by passive immunization. Trans R Soc Trop Med Hyg 1985; 79:380.</a></li><li><a class="nounderline abstract_t">Baize S, Marianneau P, Loth P, et al. Early and strong immune responses are associated with control of viral replication and recovery in lassa virus-infected cynomolgus monkeys. J Virol 2009; 83:5890.</a></li><li><a class="nounderline abstract_t">Port JR, Wozniak DM, Oestereich L, et al. Severe Human Lassa Fever Is Characterized by Nonspecific T-Cell Activation and Lymphocyte Homing to Inflamed Tissues. J Virol 2020; 94.</a></li><li><a class="nounderline abstract_t">Mahanty S, Bausch DG, Thomas RL, et al. Low levels of interleukin-8 and interferon-inducible protein-10 in serum are associated with fatal infections in acute Lassa fever. J Infect Dis 2001; 183:1713.</a></li><li><a class="nounderline abstract_t">Lukashevich IS, Maryankova R, Vladyko AS, et al. Lassa and Mopeia virus replication in human monocytes/macrophages and in endothelial cells: different effects on IL-8 and TNF-alpha gene expression. J Med Virol 1999; 59:552.</a></li><li><a class="nounderline abstract_t">Mertens PE, Patton R, Baum JJ, Monath TP. Clinical presentation of Lassa fever cases during the hospital epidemic at Zorzor, Liberia, March-April 1972. Am J Trop Med Hyg 1973; 22:780.</a></li><li><a class="nounderline abstract_t">Monath TP, Maher M, Casals J, et al. Lassa fever in the Eastern Province of Sierra Leone, 1970-1972. II. Clinical observations and virological studies on selected hospital cases. Am J Trop Med Hyg 1974; 23:1140.</a></li><li><a class="nounderline abstract_t">Monson MH, Frame JD, Jahrling PB, Alexander K. Endemic Lassa fever in Liberia. I. Clinical and epidemiological aspects at Curran Lutheran Hospital, Zorzor, Liberia. Trans R Soc Trop Med Hyg 1984; 78:549.</a></li><li class="breakAll">World Health Organization. Lassa fever. http://www.who.int/mediacentre/factsheets/fs179/en/ (Accessed on August 03, 2016).</li><li><a class="nounderline abstract_t">Cummins D, McCormick JB, Bennett D, et al. Acute sensorineural deafness in Lassa fever. JAMA 1990; 264:2093.</a></li><li><a class="nounderline abstract_t">Khan SH, Goba A, Chu M, et al. New opportunities for field research on the pathogenesis and treatment of Lassa fever. Antiviral Res 2008; 78:103.</a></li><li><a class="nounderline abstract_t">Okokhere PO, Ibekwe TS, Akpede GO. Sensorineural hearing loss in Lassa fever: two case reports. J Med Case Rep 2009; 3:36.</a></li><li><a class="nounderline abstract_t">Liao BS, Byl FM, Adour KK. Audiometric comparison of Lassa fever hearing loss and idiopathic sudden hearing loss: evidence for viral cause. Otolaryngol Head Neck Surg 1992; 106:226.</a></li><li><a class="nounderline abstract_t">McCormick JB. Clinical, epidemiologic, and therapeutic aspects of Lassa fever. Med Microbiol Immunol 1986; 175:153.</a></li><li><a class="nounderline abstract_t">Branco LM, Grove JN, Boisen ML, et al. Emerging trends in Lassa fever: redefining the role of immunoglobulin M and inflammation in diagnosing acute infection. Virol J 2011; 8:478.</a></li><li><a class="nounderline abstract_t">Okokhere P, Colubri A, Azubike C, et al. Clinical and laboratory predictors of Lassa fever outcome in a dedicated treatment facility in Nigeria: a retrospective, observational cohort study. Lancet Infect Dis 2018; 18:684.</a></li><li><a class="nounderline abstract_t">Grahn A, Bråve A, Lagging M, et al. Imported Case of Lassa Fever in Sweden With Encephalopathy and Sensorineural Hearing Deficit. Open Forum Infect Dis 2016; 3:ofw198.</a></li><li><a class="nounderline abstract_t">Solbrig MV. Headache syndromes in Sierra Leone, West Africa. Headache 1991; 31:419.</a></li><li><a class="nounderline abstract_t">Hirabayashi Y, Oka S, Goto H, et al. An imported case of Lassa fever with late appearance of polyserositis. J Infect Dis 1988; 158:872.</a></li><li><a class="nounderline abstract_t">Yanase O, Motomiya T, Watanabe K, et al. [Lassa fever associated with effusive constrictive pericarditis and bilateral atrioventricular annular constriction: a case report]. J Cardiol 1989; 19:1147.</a></li><li><a class="nounderline abstract_t">Cummins D, Bennett D, Fisher-Hoch SP, et al. Electrocardiographic abnormalities in patients with Lassa fever. J Trop Med Hyg 1989; 92:350.</a></li><li><a class="nounderline abstract_t">Cummins D, Fisher-Hoch SP, Walshe KJ, et al. A plasma inhibitor of platelet aggregation in patients with Lassa fever. Br J Haematol 1989; 72:543.</a></li><li><a class="nounderline abstract_t">Lange JV, Mitchell SW, McCormick JB, et al. Kinetic study of platelets and fibrinogen in Lassa virus-infected monkeys and early pathologic events in Mopeia virus-infected monkeys. Am J Trop Med Hyg 1985; 34:999.</a></li><li><a class="nounderline abstract_t">Price ME, Fisher-Hoch SP, Craven RB, McCormick JB. A prospective study of maternal and fetal outcome in acute Lassa fever infection during pregnancy. BMJ 1988; 297:584.</a></li><li><a class="nounderline abstract_t">Kayem ND, Benson C, Aye CYL, et al. Lassa fever in pregnancy: a systematic review and meta-analysis. Trans R Soc Trop Med Hyg 2020; 114:385.</a></li><li><a class="nounderline abstract_t">Monson MH, Cole AK, Frame JD, et al. Pediatric Lassa fever: a review of 33 Liberian cases. Am J Trop Med Hyg 1987; 36:408.</a></li><li><a class="nounderline abstract_t">Schmitz H, Köhler B, Laue T, et al. Monitoring of clinical and laboratory data in two cases of imported Lassa fever. Microbes Infect 2002; 4:43.</a></li><li><a class="nounderline abstract_t">Frame JD. Clinical features of Lassa fever in Liberia. Rev Infect Dis 1989; 11 Suppl 4:S783.</a></li><li><a class="nounderline abstract_t">McCormick JB, King IJ, Webb PA, et al. Lassa fever. Effective therapy with ribavirin. N Engl J Med 1986; 314:20.</a></li><li><a class="nounderline abstract_t">Asogun DA, Adomeh DI, Ehimuan J, et al. Molecular diagnostics for lassa fever at Irrua specialist teaching hospital, Nigeria: lessons learnt from two years of laboratory operation. PLoS Negl Trop Dis 2012; 6:e1839.</a></li><li><a class="nounderline abstract_t">Günther S, Weisner B, Roth A, et al. Lassa fever encephalopathy: Lassa virus in cerebrospinal fluid but not in serum. J Infect Dis 2001; 184:345.</a></li><li><a class="nounderline abstract_t">Vieth S, Drosten C, Lenz O, et al. RT-PCR assay for detection of Lassa virus and related Old World arenaviruses targeting the L gene. Trans R Soc Trop Med Hyg 2007; 101:1253.</a></li><li><a class="nounderline abstract_t">Olschläger S, Lelke M, Emmerich P, et al. Improved detection of Lassa virus by reverse transcription-PCR targeting the 5' region of S RNA. J Clin Microbiol 2010; 48:2009.</a></li><li><a class="nounderline abstract_t">Manning JT, Forrester N, Paessler S. Lassa virus isolates from Mali and the Ivory Coast represent an emerging fifth lineage. Front Microbiol 2015; 6:1037.</a></li><li><a class="nounderline abstract_t">Wiley MR, Fakoli L, Letizia AG, et al. Lassa virus circulating in Liberia: a retrospective genomic characterisation. Lancet Infect Dis 2019; 19:1371.</a></li><li class="breakAll">Centers for Disease Control and Prevention. Lassa Fever: Diagnosis. https://www.cdc.gov/vhf/lassa/diagnosis/index.html (Accessed on August 02, 2016).</li><li><a class="nounderline abstract_t">Wulff H, Johnson KM. Immunoglobulin M and G responses measured by immunofluorescence in patients with Lassa or Marburg virus infections. Bull World Health Organ 1979; 57:631.</a></li><li><a class="nounderline abstract_t">Emmerich P, Günther S, Schmitz H. Strain-specific antibody response to Lassa virus in the local population of west Africa. J Clin Virol 2008; 42:40.</a></li><li><a class="nounderline abstract_t">Boggild AK, Esposito DH, Kozarsky PE, et al. Differential diagnosis of illness in travelers arriving from Sierra Leone, Liberia, or Guinea: a cross-sectional study from the GeoSentinel Surveillance Network. Ann Intern Med 2015; 162:757.</a></li><li class="breakAll">World Health Organization. Clinical management of patients with viral haemorrhagic fever: A pocket guide for front-line health workers. https://apps.who.int/iris/bitstream/handle/10665/205570/9789241549608_eng.pdf (Accessed on May 18, 2022).</li><li class="breakAll">Connor JD, Hintz M, Van Dyke R, et al. Ribavirin Pharmacokinetics in Children and Adults During Therapeutic Trials, Academic Press, Orlando, FL 1984.</li><li><a class="nounderline abstract_t">Erameh C, Edeawe O, Akhideno P, et al. Prospective observational study on the pharmacokinetic properties of the Irrua ribavirin regimen used in routine clinical practice in patients with Lassa fever in Nigeria. BMJ Open 2020; 10:e036936.</a></li><li><a class="nounderline abstract_t">Haas WH, Breuer T, Pfaff G, et al. Imported Lassa fever in Germany: surveillance and management of contact persons. Clin Infect Dis 2003; 36:1254.</a></li><li><a class="nounderline abstract_t">Salam AP, Cheng V, Edwards T, et al. Time to reconsider the role of ribavirin in Lassa fever. PLoS Negl Trop Dis 2021; 15:e0009522.</a></li><li><a class="nounderline abstract_t">Salam AP, Duvignaud A, Jaspard M, et al. Ribavirin for treating Lassa fever: A systematic review of pre-clinical studies and implications for human dosing. PLoS Negl Trop Dis 2022; 16:e0010289.</a></li><li><a class="nounderline abstract_t">Eberhardt KA, Mischlinger J, Jordan S, et al. Ribavirin for the treatment of Lassa fever: A systematic review and meta-analysis. Int J Infect Dis 2019; 87:15.</a></li><li class="breakAll">Birch &amp; Davis Associates and Sherikon Inc. on behalf of the U.S. Army Medical Research and Development Command. Final Report Analysis of a Clinical Trial Ribavirin and the Treatment of Lassa Fever. Report No.: IND 16666. Maryland, USA; 1992. https://media.tghn.org/medialibrary/2019/03/Responsive_Documents_of_Peter_Horby.pdf.pdf (Accessed on June 01, 2022).</li><li><a class="nounderline abstract_t">Cheng HY, French CE, Salam AP, et al. Lack of Evidence for Ribavirin Treatment of Lassa Fever in Systematic Review of Published and Unpublished Studies1. Emerg Infect Dis 2022; 28:1559.</a></li><li><a class="nounderline abstract_t">Groger M, Akhideno P, Kleist CJ, et al. Pharmacokinetics of Ribavirin in the Treatment of Lassa Fever: An Observational Clinical Study at the Irrua Specialist Teaching Hospital, Edo State, Nigeria. Clin Infect Dis 2023; 76:e841.</a></li><li><a class="nounderline abstract_t">Lukashevich IS. Advanced vaccine candidates for Lassa fever. Viruses 2012; 4:2514.</a></li><li class="breakAll">Centers for Disease Control and Prevention. Viral Hemorrhagic Fevers (VHFs): Information for Healthcare Workers. http://www.cdc.gov/vhf/abroad/healthcare-workers.html (Accessed on August 04, 2016).</li><li><a class="nounderline abstract_t">Bausch DG, Hadi CM, Khan SH, Lertora JJ. Review of the literature and proposed guidelines for the use of oral ribavirin as postexposure prophylaxis for Lassa fever. Clin Infect Dis 2010; 51:1435.</a></li><li><a class="nounderline abstract_t">Huggins JW. Prospects for treatment of viral hemorrhagic fevers with ribavirin, a broad-spectrum antiviral drug. Rev Infect Dis 1989; 11 Suppl 4:S750.</a></li><li><a class="nounderline abstract_t">Bossi P, Tegnell A, Baka A, et al. Bichat guidelines for the clinical management of haemorrhagic fever viruses and bioterrorism-related haemorrhagic fever viruses. Euro Surveill 2004; 9:E11.</a></li><li><a class="nounderline abstract_t">Crowcroft NS. Management of Lassa fever in European countries. Euro Surveill 2002; 7:50.</a></li><li><a class="nounderline abstract_t">Holmes GP, McCormick JB, Trock SC, et al. Lassa fever in the United States. Investigation of a case and new guidelines for management. N Engl J Med 1990; 323:1120.</a></li></ol></div><div id="topicVersionRevision">Topic 103771 Version 17.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10888638" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Genetic diversity among Lassa virus strains.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14972544" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Sequence analysis of L RNA of Lassa virus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16568904" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Arenavirus diversity and evolution: quasispecies in vivo.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3805771" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : A prospective study of the epidemiology and ecology of Lassa fever.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14644972" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Lassa fever: epidemiology, clinical features, and social consequences.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4246571" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Lassa fever, a new virus disease of man from West Africa. I. Clinical description and pathological findings.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4987549" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : An outbreak of Lassa fever on the Jos plateau, Nigeria, in January-February 1970. A preliminary report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4987546" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Lassa fever, a new virus disease of man from West Africa. II. Report of a laboratory-acquired infection treated with plasma from a person recently recovered from the disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5428406" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Isolation and antigenic characterization of Lassa virus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5046379" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Lassa fever. A study of 23 hospital cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5046380" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Lassa fever. Epidemiological aspects of the 1970 epidemic, Jos, Nigeria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1085214" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Lassa fever in Onitsha, East Central State, Nigeria in 1974.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4833828" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Lassa virus isolation from Mastomys natalensis rodents during an epidemic in Sierra Leone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12120480" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Threats in bioterrorism. I: CDC category A agents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1085225" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Diagnosis of Lassa fever and the isolation and management of patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17378212" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Lassa fever in West African sub-region: an overview.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19255625" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Risk maps of Lassa fever in West Africa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10998376" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Imported lassa fever in Germany: molecular characterization of a new lassa virus strain.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23661832" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : The first cases of Lassa fever in Ghana.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19317988" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : The first case of Lassa fever imported from Mali to the United Kingdom, February 2009.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20587185" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Detection of Lassa virus, Mali.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24340119" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Geographic distribution and genetic characterization of Lassa virus in sub-Saharan Mali.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26981786" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Lassa Virus Seroprevalence in Sibirilia Commune, Bougouni District, Southern Mali.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26981786" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Lassa Virus Seroprevalence in Sibirilia Commune, Bougouni District, Southern Mali.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26981786" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Lassa Virus Seroprevalence in Sibirilia Commune, Bougouni District, Southern Mali.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26981786" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Lassa Virus Seroprevalence in Sibirilia Commune, Bougouni District, Southern Mali.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12653127" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Lassa fever in Guinea: I. Epidemiology of human disease and clinical observations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19924222" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Prevalence and risk factors of Lassa seropositivity in inhabitants of the forest region of Guinea: a cross-sectional study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23279760" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Seroepidemiological study reveals regional co-occurrence of Lassa- and Hantavirus antibodies in Upper Guinea, West Africa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8355019" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Lassa virus activity in Guinea: distribution of human antiviral antibody defined using enzyme-linked immunosorbent assay with recombinant antigen.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24651047" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Lassa fever in post-conflict sierra leone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3805772" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : A case-control study of the clinical diagnosis and course of Lassa fever.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3805772" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : A case-control study of the clinical diagnosis and course of Lassa fever.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30332564" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Genomic Analysis of Lassa Virus during an Increase in Cases in Nigeria in 2018.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36584167" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Epidemiological trends of Lassa fever in Nigeria, 2018-2021.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30062993" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Case Report: Imported Case of Lassa Fever - New Jersey, May 2015.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30666924" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Lassa Fever in Travelers from West Africa, 1969-2016.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17620650" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Poor housing quality increases risk of rodent infestation and Lassa fever in refugee camps of Sierra Leone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6881432" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Case-control study of Mastomys natalensis and humans in Lassa virus-infected households in Sierra Leone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9025695" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Hunting of peridomestic rodents and consumption of their meat as possible risk factors for rodent-to-human transmission of Lassa virus in the Republic of Guinea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3805773" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Clinical virology of Lassa fever in hospitalized patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3805773" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Clinical virology of Lassa fever in hospitalized patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2279999" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Detection of Lassa virus RNA in specimens from patients with Lassa fever by using the polymerase chain reaction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2279999" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Detection of Lassa virus RNA in specimens from patients with Lassa fever by using the polymerase chain reaction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6512508" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Effect of environmental factors on aerosol-induced Lassa virus infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4745236" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : A hospital epidemic of Lassa fever in Zorzor, Liberia, March-April 1972.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7580496" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Review of cases of nosocomial Lassa fever in Nigeria: the high price of poor medical practice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10878062" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Diagnosis and clinical virology of Lassa fever as evaluated by enzyme-linked immunosorbent assay, indirect fluorescent-antibody test, and virus isolation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6768812" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Lassa virus infection of rhesus monkeys: pathogenesis and treatment with ribavirin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7125056" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Pathology of Lassa virus infection in the rhesus monkey.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7081389" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Pathologic and virologic study of fatal Lassa fever in man.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34463715" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Pathology and Pathogenesis of Lassa Fever: Novel Immunohistochemical Findings in Fatal Cases and Clinico-pathologic Correlation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3953952" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Lassa virus hepatitis: a study of fatal Lassa fever in humans.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33079033" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Endotheliopathy and Platelet Dysfunction as Hallmarks of Fatal Lassa Fever.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3034512" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Experimental studies of arenaviral hemorrhagic fevers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2554951" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Plasma from patients with severe Lassa fever profoundly modulates f-met-leu-phe induced superoxide generation in neutrophils.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11773391" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Alterations in NF-kappaB and RBP-Jkappa by arenavirus infection of macrophages in vitro and in vivo.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5046378" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : The pathology of Lassa fever.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3183637" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Hematologic dysfunction in Lassa fever.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7883875" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Early diagnosis of Lassa fever by reverse transcription-PCR.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8357084" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Evaluation of the polymerase chain reaction for diagnosis of Lassa virus infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3898484" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Endemic Lassa fever in Liberia. IV. Selection of optimally effective plasma for treatment by passive immunization.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19297492" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Early and strong immune responses are associated with control of viral replication and recovery in lassa virus-infected cynomolgus monkeys.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32817220" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Severe Human Lassa Fever Is Characterized by Nonspecific T-Cell Activation and Lymphocyte Homing to Inflamed Tissues.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11372023" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Low levels of interleukin-8 and interferon-inducible protein-10 in serum are associated with fatal infections in acute Lassa fever.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10534741" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Lassa and Mopeia virus replication in human monocytes/macrophages and in endothelial cells: different effects on IL-8 and TNF-alpha gene expression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4745237" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Clinical presentation of Lassa fever cases during the hospital epidemic at Zorzor, Liberia, March-April 1972.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4429183" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Lassa fever in the Eastern Province of Sierra Leone, 1970-1972. II. Clinical observations and virological studies on selected hospital cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6485062" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Endemic Lassa fever in Liberia. I. Clinical and epidemiological aspects at Curran Lutheran Hospital, Zorzor, Liberia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6485062" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Endemic Lassa fever in Liberia. I. Clinical and epidemiological aspects at Curran Lutheran Hospital, Zorzor, Liberia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2214077" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Acute sensorineural deafness in Lassa fever.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18241935" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : New opportunities for field research on the pathogenesis and treatment of Lassa fever.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19178735" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Sensorineural hearing loss in Lassa fever: two case reports.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1589210" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Audiometric comparison of Lassa fever hearing loss and idiopathic sudden hearing loss: evidence for viral cause.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3724661" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Clinical, epidemiologic, and therapeutic aspects of Lassa fever.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22023795" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Emerging trends in Lassa fever: redefining the role of immunoglobulin M and inflammation in diagnosing acute infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29523497" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Clinical and laboratory predictors of Lassa fever outcome in a dedicated treatment facility in Nigeria: a retrospective, observational cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27975074" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Imported Case of Lassa Fever in Sweden With Encephalopathy and Sensorineural Hearing Deficit.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1889986" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Headache syndromes in Sierra Leone, West Africa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3171229" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : An imported case of Lassa fever with late appearance of polyserositis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2486633" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : [Lassa fever associated with effusive constrictive pericarditis and bilateral atrioventricular annular constriction: a case report].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2810453" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Electrocardiographic abnormalities in patients with Lassa fever.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2775659" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : A plasma inhibitor of platelet aggregation in patients with Lassa fever.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4037187" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Kinetic study of platelets and fibrinogen in Lassa virus-infected monkeys and early pathologic events in Mopeia virus-infected monkeys.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3139220" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : A prospective study of maternal and fetal outcome in acute Lassa fever infection during pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32125412" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Lassa fever in pregnancy: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3826501" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Pediatric Lassa fever: a review of 33 Liberian cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11825774" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Monitoring of clinical and laboratory data in two cases of imported Lassa fever.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2749109" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Clinical features of Lassa fever in Liberia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3940312" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Lassa fever. Effective therapy with ribavirin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23029594" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Molecular diagnostics for lassa fever at Irrua specialist teaching hospital, Nigeria: lessons learnt from two years of laboratory operation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11443561" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Lassa fever encephalopathy: Lassa virus in cerebrospinal fluid but not in serum.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17905372" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : RT-PCR assay for detection of Lassa virus and related Old World arenaviruses targeting the L gene.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20351210" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Improved detection of Lassa virus by reverse transcription-PCR targeting the 5' region of S RNA.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26483768" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Lassa virus isolates from Mali and the Ivory Coast represent an emerging fifth lineage.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31588039" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Lassa virus circulating in Liberia: a retrospective genomic characterisation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31588039" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Lassa virus circulating in Liberia: a retrospective genomic characterisation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/118812" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Immunoglobulin M and G responses measured by immunofluorescence in patients with Lassa or Marburg virus infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18164653" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Strain-specific antibody response to Lassa virus in the local population of west Africa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25961811" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Differential diagnosis of illness in travelers arriving from Sierra Leone, Liberia, or Guinea: a cross-sectional study from the GeoSentinel Surveillance Network.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25961811" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Differential diagnosis of illness in travelers arriving from Sierra Leone, Liberia, or Guinea: a cross-sectional study from the GeoSentinel Surveillance Network.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25961811" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Differential diagnosis of illness in travelers arriving from Sierra Leone, Liberia, or Guinea: a cross-sectional study from the GeoSentinel Surveillance Network.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32303517" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Prospective observational study on the pharmacokinetic properties of the Irrua ribavirin regimen used in routine clinical practice in patients with Lassa fever in Nigeria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12746770" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Imported Lassa fever in Germany: surveillance and management of contact persons.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34237063" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Time to reconsider the role of ribavirin in Lassa fever.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35353804" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Ribavirin for treating Lassa fever: A systematic review of pre-clinical studies and implications for human dosing.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31357056" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Ribavirin for the treatment of Lassa fever: A systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31357056" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Ribavirin for the treatment of Lassa fever: A systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35876478" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Lack of Evidence for Ribavirin Treatment of Lassa Fever in Systematic Review of Published and Unpublished Studies1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35881530" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Pharmacokinetics of Ribavirin in the Treatment of Lassa Fever: An Observational Clinical Study at the Irrua Specialist Teaching Hospital, Edo State, Nigeria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23202493" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : Advanced vaccine candidates for Lassa fever.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23202493" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : Advanced vaccine candidates for Lassa fever.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21058912" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : Review of the literature and proposed guidelines for the use of oral ribavirin as postexposure prophylaxis for Lassa fever.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2546248" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : Prospects for treatment of viral hemorrhagic fevers with ribavirin, a broad-spectrum antiviral drug.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15677844" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : Bichat guidelines for the clinical management of haemorrhagic fever viruses and bioterrorism-related haemorrhagic fever viruses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12631947" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : Management of Lassa fever in European countries.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2215580" id="rid116" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>117 : Lassa fever in the United States. Investigation of a case and new guidelines for management.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
